Furthermore, dysregulation of the HGF-MET pathway has been demonstrated in malignancies of epithelial cell origin, represented by carcinomas of the lung, mamma, hepatic cells, pancreas ovaries, papillary renal carcinoma, papillary thyroid carcinoma, and carcinomas of the colorectal system.[6]Dysregulation of the HGF-MET cellular axis may due to MET gene mutations, MET amplification, chromosomal rearrangement, MET transcriptional upregulation or changes in the autocrine or paracrine signaling. The gene discussed is MET; the disease is lung carcinoma.